0001729149false00017291492024-11-062024-11-06

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2024
 
Viemed Healthcare, Inc.
(Exact name of registrant as specified in its charter)
  
British Columbia, Canada
001-38973N/A
(State or other jurisdiction
of incorporation)		(Commission
File Number)		(I.R.S. Employer
Identification No.)
625 E. Kaliste Saloom Rd.
Lafayette, Louisiana
70508
(Address of principal executive offices)(Zip Code)
(337) 504-3802
(Registrant’s telephone number, including area code) 


(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common shares, no par value
VMD
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 2.02.     Results of Operations and Financial Condition.

On November 6, 2024, Viemed Healthcare, Inc. (the "Company") issued a press release announcing its financial results for the three and nine months ended September 30, 2024. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the foregoing information, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information and Exhibit 99.1 be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01.    Financial Statements and Exhibits
(d)Exhibits
 
Exhibit
Number
Description
104     Cover Page Interactive Data File, formatted in Inline XBRL and included as Exhibit 101


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 6, 2024
 
VIEMED HEALTHCARE, INC.
By:
/s/ Trae Fitzgerald
Trae Fitzgerald
Chief Financial Officer

































VIEMED HEALTHCARE ANNOUNCES THIRD QUARTER 2024 FINANCIAL RESULTS

Lafayette, Louisiana (November 6, 2024) Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three and nine months ended September 30, 2024.

Operational highlights (all dollar amounts are USD; comparisons are to the period ended September 30, 2023 unless otherwise noted):

•Net revenues increased 17.4% for the quarter ended September 30, 2024 to $58.0 million, setting another Company record, and increased 5.5% sequentially over the second quarter ended June 30, 2024. Excluding acquired revenue of $1.1 million, non-acquired net revenues increased by 15% for the quarter ended September 30, 2024.

•Net income increased 33% for the quarter ended September 30, 2024 to $3.9 million, or $0.10 per diluted share. Adjusted EBITDA for the quarter ended September 30, 2024 increased 15.5% to $14.0 million. A reconciliation of reported non-GAAP financial measures to their most directly comparable U.S. GAAP financial measures can be found in the tables accompanying this press release.

•The Company increased its ventilator patient count by 11.0% to 11,374 on September 30, 2024 and increased ventilator patient count by 4.3% sequentially from June 30, 2024.

•The Company increased its sleep therapy patient count by 11.0% sequentially to 19,478 on September 30, 2024; the Company also increased its sleep resupply orders by 9.7% sequentially to 22,143 on September 30, 2024.

•As of September 30, 2024, the Company maintains a strong cash balance of $11.3 million and an overall working capital balance of $11.3 million. Long term debt as of September 30, 2024 amounted to $3.7 million and the Company has $55.3 million available under existing credit facilities.

•The Company exceeded the high end of its previously projected net revenue range for the third quarter of 2024, and now expects to generate net revenues of approximately $59.7 million to $60.9 million during the fourth quarter of 2024.

Casey Hoyt, Viemed’s CEO, noted, “Viemed continues to earn a trusted place in the home with our high-touch, technology-enabled clinical approach to delivering complex respiratory care services. As a vital link between patients, providers and payers, we are demonstrating Viemed’s value in increasing patient satisfaction, improving compliance, and reducing rehospitalizations. This valuable position is helping us increase the patient population that we can serve for non-invasive ventilation, sleep, staffing and other complementary services.

“The combination of Viemed’s well-earned place in the home, the sales force restructuring initiatives we completed earlier this year, and the operational efficiencies facilitating greater patient compliance are fueling our strong organic revenue growth. The improved outlook for the balance of 2024 is predicated on continued benefits from these sales initiatives and operational efficiencies driving organic growth and greater penetration of our underserved markets through expanded service and home-based product offerings,” added Mr. Hoyt.

Conference Call Details

The Company will host a conference call to discuss third quarter results on Thursday, November 7, 2024 at 12:00 p.m. ET.

Interested parties may participate in the call by dialing:

877-407-6176 (US Toll-Free)
+1 201-689-8451 (International)

Live Audio Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=qSIpA5NC

Following the conclusion of the call, an audio recording and transcript of the call can be accessed on the Company's website.



ABOUT VIEMED HEALTHCARE, INC.

Viemed is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. Viemed focuses on efficient and effective in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. Visit our website at www.viemed.com.

For further information, please contact:

Glen Akselrod
Bristol Capital
905-326-1888
glen@bristolir.com

Todd Zehnder
Chief Operating Officer
Viemed Healthcare, Inc.
337-504-3802
investorinfo@viemed.com




Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian securities legislation (collectively, “forward-looking statements”). Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “projects”, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “will”, “should”, “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's net revenue guidance for the fourth quarter, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which the Company operates; significant capital requirements and operating risks that the Company may be subject to; the ability of the Company to implement business strategies and pursue business opportunities; volatility in the market price of the Company's common shares; the state of the capital markets; the availability of funds and resources to pursue operations; inflation; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the Company’s status as an emerging growth company; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, and claims resulting from such events or concerns; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the U.S. Securities and Exchange Commission (the “SEC”) available on the SEC’s website at www.sec.gov, including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at www.sedar.com. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.



VIEMED HEALTHCARE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Expressed in thousands of U.S. Dollars, except share amounts)
(Unaudited)
At
September 30, 2024		At
December 31, 2023
ASSETS
Current assets
Cash and cash equivalents$11,347 $12,839 
Accounts receivable, net27,051 18,451 
Inventory4,311 4,628 
Prepaid expenses and other assets4,989 2,449 
Total current assets$47,698 $38,367 
Long-term assets
Property and equipment, net74,397 73,579 
Finance lease right-of-use assets70 401 
Operating lease right-of-use assets2,758 2,872 
Equity investments1,794 1,680 
Debt investment875 2,219 
Deferred tax asset8,065 4,558 
Identifiable intangibles, net880 567 
Goodwill32,989 29,765 
Other long-term assets— 887 
Total long-term assets$121,828 $116,528 
TOTAL ASSETS$169,526 $154,895 
LIABILITIES
Current liabilities
Trade payables$6,007 $4,180 
Deferred revenue6,819 6,207 
Income taxes payable2,077 2,153 
Accrued liabilities19,918 17,578 
Finance lease liabilities, current portion69 256 
Operating lease liabilities, current portion 742 678 
Current portion of long-term debt812 1,072 
Total current liabilities$36,444 $32,124 
Long-term liabilities
Accrued liabilities652 558 
Finance lease liabilities, less current portion — 132 
Operating lease liabilities, less current portion1,985 2,184 
Long-term debt3,650 6,002 
Total long-term liabilities$6,287 $8,876 
TOTAL LIABILITIES$42,731 $41,000 
Commitments and Contingencies— — 
SHAREHOLDERS' EQUITY
Common stock - No par value: unlimited authorized; 38,932,247 and 38,506,161 issued and outstanding as of September 30, 2024 and December 31, 2023, respectively
22,749 18,702 
Additional paid-in capital16,831 15,698 
Retained earnings85,379 79,495 
TOTAL VIEMED HEALTHCARE, INC.'S SHAREHOLDERS' EQUITY$124,959 $113,895 
Noncontrolling interest in subsidiary
1,836 — 
TOTAL SHAREHOLDERS' EQUITY 126,795 113,895 
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY$169,526 $154,895 


VIEMED HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Expressed in thousands of U.S. Dollars, except outstanding shares and per share amounts)
(Unaudited)
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Revenue$58,004 $49,402 $163,562 $132,269 
Cost of revenue23,633 18,840 66,497 51,597 
Gross profit$34,371 $30,562 $97,065 $80,672 
Operating expenses
Selling, general and administrative26,671 23,654 77,988 63,979 
Research and development757 593 2,265 2,131 
Stock-based compensation1,712 1,453 4,764 4,315 
Depreciation and amortization
348 419 1,140 957 
Loss (gain) on disposal of property and equipment
(469)278 (801)373 
     Other expense (income), net
(276)(41)261 (124)
Income from operations$5,628 $4,206 $11,448 $9,041 
Non-operating income and expenses
Income (expense) from investments
96 270 (954)442 
Interest expense, net
(225)(237)(629)(168)
Net income before taxes5,499 4,239 9,865 9,315 
Provision for income taxes1,594 1,320 2,880 2,549 
Net income$3,905 $2,919 $6,985 $6,766 
Net income attributable to noncontrolling interest
27 — 36 — 
Net income attributable to Viemed Healthcare, Inc.
$3,878 $2,919 $6,949 $6,766 
Net income per share
Basic$0.10 $0.08 $0.18 $0.18 
Diluted$0.10 $0.07 $0.17 $0.17 
Weighted average number of common shares outstanding:
Basic 38,870,823 38,438,058 38,803,887 38,307,343 
Diluted40,779,414 40,420,615 40,702,001 40,391,729 


VIEMED HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Expressed in thousands of U.S. Dollars)
(Unaudited)
Nine Months Ended September 30,
20242023
Cash flows from operating activities
Net income$6,985 $6,766 
Adjustments for:
Depreciation and amortization
19,002 15,943 
Stock-based compensation expense4,764 4,315 
Distributions of earnings received from equity method investments147 833 
Income from equity method investments(261)(442)
Loss (income) from debt investment
1,344 (164)
Loss (gain) on disposal of property and equipment
(801)373 
Amortization of deferred financing costs
135 — 
Deferred income tax benefit
(3,507)(791)
Changes in working capital:
Accounts receivable, net(8,213)(533)
Inventory583 (514)
Prepaid expenses and other assets340 1,193 
Trade payables747 (255)
Deferred revenue489 859 
Accrued liabilities2,424 4,086 
Income tax payable/receivable(76)259 
Net cash provided by operating activities$24,102 $31,928 
Cash flows from investing activities
Purchase of property and equipment(25,942)(18,161)
Investment in equity investments— (7)
Cash paid for acquisitions, net of cash acquired
(2,999)(28,580)
Proceeds from sale of property and equipment7,440 2,128 
Net cash used in investing activities$(21,501)$(44,620)
Cash flows from financing activities
Proceeds from exercise of options416 1,234 
Proceeds from term notes— 5,000 
Principal payments on term notes(954)(2,746)
Proceeds from revolving credit facilities3,000 8,000 
Payments on revolving credit facilities(5,000)(5,005)
Payments for debt issuance costs
(171)— 
Shares redeemed to pay income tax(1,065)(595)
Repayments of finance lease liabilities
(319)(32)
Net cash provided by (used in) financing activities
$(4,093)$5,856 
Net decrease in cash and cash equivalents(1,492)(6,836)
Cash and cash equivalents at beginning of year12,839 16,914 
Cash and cash equivalents at end of period$11,347 $10,078 
Supplemental disclosures of cash flow information
Cash paid during the period for interest$745 $497 
Cash paid during the period for income taxes, net of refunds
$6,416 $3,218 
Supplemental disclosures of non-cash transactions
Equipment and other fixed asset purchases payable at end of period
$2,854 $2,598 
Equipment sales receivable at end of period
$1,683 $— 


Non-GAAP Financial Measures

This press release refers to “Adjusted EBITDA”, which is a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). Adjusted EBITDA should be considered in addition to, not as a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP. Management believes Adjusted EBITDA provides helpful information with respect to the Company’s operating performance as viewed by management, including a view of the Company’s business that is not dependent on the impact of the Company’s capitalization structure and items that are not part of the Company’s day-to-day operations. Management uses Adjusted EBITDA (i) to compare the Company’s operating performance on a consistent basis, (ii) to calculate incentive compensation for the Company’s employees, (iii) for planning purposes, including the preparation of the Company’s internal annual operating budget, and (iv) to evaluate the performance and effectiveness of the Company’s operational strategies. Accordingly, management believes that Adjusted EBITDA provides useful information in understanding and evaluating the Company’s operating performance in the same manner as management. Adjusted EBITDA is not a measurement of the Company’s financial performance under U.S. GAAP and should not be considered as an alternative to revenue or net income, as applicable, or any other performance measures derived in accordance with U.S. GAAP. Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of the Company’s operating results as reported under U.S. GAAP. Adjusted EBITDA does not reflect the impact of certain cash charges resulting from matters the Company considers not to be indicative of ongoing operations; and other companies in the Company’s industry may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure. In calculating Adjusted EBITDA, certain items (mostly non-cash) are excluded from net income including depreciation and amortization of capitalized assets, net interest expense (income), stock based compensation, transaction costs, impairment of assets, and taxes.

The following table is a reconciliation of net income (loss), the most directly comparable U.S. GAAP measure, to Adjusted EBITDA, on a historical basis for the periods indicated:

VIEMED HEALTHCARE, INC.
Reconciliation of Net Income to Non-GAAP Adjusted EBITDA
(Expressed in thousands of U.S. Dollars)
(Unaudited)
For the quarter endedSeptember 30, 2024June 30, 2024March 31, 2024December 31, 2023September 30, 2023June 30, 2023March 31, 2023December 31, 2022
Net income attributable to Viemed Healthcare, Inc.
$3,878 $1,468 $1,603 $3,477 $2,919 $2,330 $1,517 $2,438 
Add back:
Depreciation & amortization
6,408 6,309 6,285 5,918 5,975 5,207 4,762 4,373 
Interest expense (income)225 254 150 256 237 (20)(49)32 
Stock-based compensation(a)
1,712 1,620 1,432 1,534 1,453 1,471 1,391 1,317 
Transaction costs(b)
12 221 110 61 177 94 206 — 
Impairment of assets(c)
125 2,173 — — — — — — 
Income tax expense1,594 768 518 1,599 1,320 728 501 1,146 
Adjusted EBITDA$13,954 $12,813 $10,098 $12,845 $12,081 $9,810 $8,328 $9,306 

(a) Represents non-cash, equity-based compensation expense associated with option and RSU awards.
(b) Represents transaction costs and expenses related to acquisition and integration efforts associated with recently announced or completed acquisitions.
(c) Represents impairments of the fair value of investment and litigation-related assets.




VIEMED HEALTHCARE, INC.
Key Financial and Operational Information
(Expressed in thousands of U.S. Dollars, except vent patients)
(Unaudited)
For the quarter endedSeptember 30,
2024		June 30, 2024March 31, 2024December 31, 2023September 30, 2023June 30, 2023March 31, 2023December 31, 2022
Financial Information:
Revenue$58,004 $54,965 $50,593 $50,739 $49,402 $43,311 $39,556 $37,508 
Gross Profit$34,371 $32,892 $29,802 $32,111 $30,562 $26,106 $24,004 $22,896 
Gross Profit %59 %60 %59 %63 %62 %60 %61 %61 %
Net Income$3,905 $1,477 $1,603 $3,477 $2,919 $2,330 $1,517 $2,438 
Cash (As of)$11,347 $8,807 $7,309 $12,839 $10,078 $10,224 $23,544 $16,914 
Total Assets (As of)$169,526 $163,947 $154,875 $154,895 $149,400 $149,117 $124,634 $117,043 
Adjusted EBITDA(1)
$13,954 $12,813 $10,098 $12,845 $12,081 $9,810 $8,328 $9,306 
Operational Information:
Vent Patients(2)
11,374 10,905 10,450 10,327 10,244 10,005 9,337 9,306 
(1)Refer to "Non-GAAP Financial Measures" section above for definition of Adjusted EBITDA.
(2)Vent Patients represents the number of active ventilator patients on recurring billing service at the end of each calendar quarter.

The revenues from each major source are summarized in the following table:

Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Revenue from rentals
    Ventilator rentals, non-invasive and invasive$31,772 $28,322 $91,404 $79,181 
    Other home medical equipment rentals12,459 11,119 35,604 26,441 
Revenue from sales and services
    Equipment and supply sales
8,440 7,742 21,956 19,287 
    Service revenues
5,333 2,219 14,598 7,360 
Total revenues$58,004 $49,402 $163,562 $132,269 



v3.24.3
Cover
Nov. 06, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Nov. 06, 2024
Entity Registrant Name Viemed Healthcare, Inc.
Entity File Number 001-38973
Entity Incorporation, State or Country Code Z4
Entity Address, Address Line One 625 E. Kaliste Saloom Rd.
Entity Address, Postal Zip Code 70508
Entity Address, City or Town Lafayette
Entity Address, State or Province LA
City Area Code 337
Local Phone Number 504-3802
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common shares, no par value
Trading Symbol VMD
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001729149
Amendment Flag false
VieMed Healthcare (NASDAQ:VMD)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024 VieMed Healthcare 차트를 더 보려면 여기를 클릭.
VieMed Healthcare (NASDAQ:VMD)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024 VieMed Healthcare 차트를 더 보려면 여기를 클릭.